Regeneron to terminate antibody discovery partnership with Sanofi at year-end
Aug. 03, 2017 9:13 AM ETRegeneron Pharmaceuticals, Inc. (REGN)By: Douglas W. House, SA News Editor14 Comments
- Regeneron Pharmaceuticals (NASDAQ:REGN) has quietly announced (in its Q2 earnings release under "Business Development Update") that its Antibody Discovery Agreement with Sanofi (SNY) will end on December 31 without any extension.
- Praluent (alirocumab), Dupixent (dupilumab), Kevzara (sarilumab) and REGN3500 will continue to be developed and commercialized as planned under the companies' collaboration.
- After year-end, Regeneron has the right to develop or continue to develop other product candidates discovered under the agreement either independently or with other collaborators. The $130M in 2017 funding provided by Sanofi will be fully used by the end of Q3.
- SNY is up a fraction premarket while REGN is up 4%, both on light volume.